ISSN: 2577-4360
Authors: Umesh Y, Prashant Kumar S*, Raj K and Shah B
With the irruption of unknown respiratory disease in Wuhan, China, in December 2019, a novel corona virus, Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), aroused the eye of the whole world and therefore the World Health Organization declared SARS-CoV-2 as public health emergency of international concern in China. Corona virus COVID-19 has affected 213 countries and territories around the world and 2 international conveyances as of June 1, 2020. 62,88,301 cases, with 3,74,327 deaths has been reported as of June 1,2020. Currently, no specific vaccine, antivirals or monoclonal antibodies available for COVID-19, although some drugs are in rapid development and may be available in a short time. Human convalescent serum is an alternative option for COVID-19 disease prevention and treatment that could be available as sufficient numbers of people (28,58,645) have recovered and are eligible to donate serum containing immunoglobulins. Administration of antibodies to the susceptible person against an exposed agent for the prevention or treatment an infectious disease because of that exposed agent is called Passive antibody therapy. Thus, passive antibody administration is the only means of providing immediate immunity to susceptible persons. This review focused on Convalescent Plasma which reduces mortality and appears to be safe. So, we suggest a well designed clinical trial should be conducted in this context.
Keywords: COVID-19; Corona virus; Passive antibody therapy; Convalescent plasma
